Identification and characterization of a deletion mutant of DNA topoisomerase I mRNA in a camptothecin-resistant subline of human colon carcinoma

Japanese Journal of Cancer Research

Volumn 91, Issue 5, 2000, Pages 551-559

  Yanase, Kae ^a,b   Sugimoto, Yoshikazu ^a   Tsukahara, Satomi ^a   Oh hara, Tomoko ^a   Andoh, Toshiwo ^b   Tsuruo, Takashi ^a,c  

^a CANCER CHEMOTHERAPY CENTER   (Japan)

^b SOKA UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Camptothecin; Deletion mutant; DNA topoisomerase I; Drug resistance

Indexed keywords

AMINO ACID; AMSACRINE; CAMPTOTHECIN; COMPLEMENTARY DNA; DNA TOPOISOMERASE; DOXORUBICIN; ETOPOSIDE; MESSENGER RNA; NUCLEOTIDE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL STRAIN 3T3; COLON CARCINOMA; CONTROLLED STUDY; DELETION MUTANT; DRUG RESISTANCE; EXON; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH CANCER;

EID: 0034041172     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2000.tb00980.x     Document Type: Article

References (47)

1. Gottlieb, J. A., Guarino, A. M., Call, J. B., Oliverio, V. T. and Block, J. B. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chemother. Rep., 54, 461-470 (1970).
2. Gottlieb, J. A. and Luce, J. K. Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother. Rep., 56, 103-105 (1972).
3. Moertel, C. G., Schutt, A. J., Reitemeier, R. J. and Hahn, R. G. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep., 56, 95-101 (1972).
4. Muggia, F. M., Creaven, P. J., Hansen, H. H., Cohen, M. H. and Selawry, O. S. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880); correlation with preclinical studies. Cancer Chemother. Rep., 56, 515-521 (1972).
5. Schaeppi, U., Fleischman, R. W. and Cooney, D. A. Toxicity of camptothecin (NSC-100880). Cancer Chemother. Rep. Part 3, 5, 25-36 (1974).
6. Kunimoto, T., Nitta, K., Tanaka, T., Uehara, N., Baba, H., Takeuchi, M., Yokokura, T., Sawada, S., Miyasaka, T. and Mutai, M. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res., 47, 5944-5947 (1987).
7. Houghton, P. J., Cheshire, P. J., Hallman, J. C., Bissery, M. C., Mathieu-Boué, A. and Houghton, J. A. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino|carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminoethyl-10-hydroxycamptothecin. Cancer Res., 53, 2823-2829 (1993).
8. Tsuruo, T., Matsuzaki, T., Matsushita, M., Saito, H. and Yokokura, T. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother. Pharmacol., 21, 71-74 (1988).
9. Maliepaard, M., van Gastelen, M. A., de Jong, L. A., Pluim, D., van Waardenburg, R. C., Ruevekamp-Helmers, M. C., Floot, B. G. and Schellens, J. H. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res., 59, 4559-4563 (1999).
10. Takahashi, T., Fujiwara, Y., Yamakido, M., Katoh, O., Watanabe, H. and Mackenzie, P. I. The role of glucuronidation in 7-ethyl-10-hydroxycamptothecin resistance in vitro. Jpn. J. Cancer Res., 88, 1211-1217 (1997).
11. ) Ohno, R., Okada, K., Masaoka, T., Kuramoto, A., Arima, T., Yoshida, Y., Ariyoshi, H., Ichimaru, M., Sakai, Y., Oguro, M., Ito, Y., Morishima, Y., Yokokura, S. and Ota, K. An early phase II study of CPT-11, a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J. Clin. Oncol., 8, 1907-1912 (1990).
12. Fukuoka, M., Niitani, H., Suzuki, A., Motomiya, M., Hasegawa, K., Nishiwaki, Y., Kuriyama, T., Ariyoshi, Y., Negoro, S., Masuda, N., Nakajima, S. and Taguchi, T. A phase H study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J. Clin. Oncol., 10, 16-20 (1992).
13. Masuda, N., Fukuoka. M., Kusunoki, Y., Matsui, K., Takafuji, N., Kudoh, S., Negoro, S., Nishioka, M., Nakagawa, K. and Takada, M. CPT-11, a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol., 10, 1225-1229 (1992).
14. Rothenberg, M. L. Efficacy and toxicity of irinotecan in patients with colorectal cancer. Semin. Oncol., 25, 39-46 (1998).
15. Bosmann, H. B. Camptothecin inhibits macromolecular synthesis in mammalian cells but not in isolated mitochondria or E. coli. Biochem. Biophys. Res. Commun., 41, 1412-1420 (1970).
16. Kessel, D. Effects of camptothecin on RNA synthesis in leukemia L1210 cells. Biochim. Biophys. Acta, 246, 225-232 (1971).
17. Horwitz, M. S. and Horwitz, S. B. Intracellular degradation of HeLa and adenovirus type 2 DNA induced by camptothecin. Biochem. Biophys. Res. Commun., 45, 723-727 (1971).
18. Hsiang, Y. H., Hertzberg, R., Hecht, S. and Liu, L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem., 260, 14873-14879 (1985).
19. Bjornsti, M. A., Benedetti, P., Viglianti, G. A. and Wang, J. C. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res., 49, 6318-6323 (1989).
20. Pommier, Y., Pourquier, P., Fan, Y. and Strumberg, D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta, 1400, 83-106 (1998).
21. Hsiang, Y. H. and Liu, L. F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res., 48, 1722-1726 (1988).
22. Redinbo, M. R., Stewart, L., Kuhn, P., Champoux, J. J. and Hol, W. G. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science, 279, 1504-1513 (1998).
23. Avemann, K., Knippers, R., Koller, T. and Sogo, J. M. Camptothecin, a specific inhibitor of type I DNA topoisomerase, induces DNA breakage at replication forks. Mol. Cell. Biol., 8, 3026-3034 (1988).
24. Hsiang, Y. H., Lihou, M. G. and Liu, L. F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complex as a mechanism of cell killing by camptothecin. Cancer Res., 49, 5077-5082 (1989).
25. Sugimoto, Y., Tsukahara, S., Oh-hara, T., Isoe, T. and Tsuruo, T. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res., 50, 6925-6930 (1990).
26. Sugimoto, Y. and Tsuruo, T. DNA-mediated transfer and cloning of human multidrug-resistant gene of Adriamycin-resistant leukemia K562. Cancer Res., 47, 2620-2625 (1987).
27. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227, 680-685 (1970).
28. Juan, C. C., Hwang, J., Liu, A. A., Whang-Peng, J., Knutsen, T., Huebner, K., Croce, C. M., Zhang, H., Wang, J. C. and Liu, L. F. Human DNA topoisomerase I is encoded by a single-copy gene that maps to chromosome region 20q12-13.2. Proc. Natl. Acad. Sci. USA, 85, 8910-8913 (1988).
29. Sugimoto, Y., Asami, N. and Tsuruo, T. Expression of P-glycoprotein mRNA in human gastric tumors. Jpn. J. Cancer Res., 80, 993-999 (1989).
30. Sugimoto, Y., Tsukahara, S., Oh-hara, T., Liu, L. F. and Tsuruo, T. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res., 50, 7962-7965 (1990).
31. Young, R. A. and Davis, R. W. Efficient isolation of genes using antibody probes. Proc. Natl. Acad. Sci. USA, 80, 1194-1198 (1983).
32. Kieffer, B. I. Optimised cDNA size selection and cloning procedure for the construction of representative plasmid cDNA libraries. Gene, 109, 115-119 (1991).
33. D'Arpa, P., Machlin, P. S., Ratrie, H., III, Rothfield, N. F., Cleveland, D. W. and Earnshaw, W. C. cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67.7-kDa carboxyl-terminal fragment. Proc. Natl. Acad. Sci. USA, 85, 2543-2547 (1988).
34. Kanegae, Y., Lee, G., Sato, Y., Tanaka, M., Nakai, M., Sakaki, T., Sugano, S. and Saito, I. Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase. Nucleic Acids Res., 23, 3816-3821 (1995).
35. Pelham, H. R. P. and Jackson, R. J. An efficient mRNA-dependent translation system from reticulocyte lysates. Eur. J. Biochem., 67, 247-256 (1976).
36. Krieg, P. and Melton, D. Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs. Nucleic Acids Res., 12, 7057-7070 (1984).
37. Ishii, K., Hasegawa, T., Fujisawa, K. and Andoh, T. Rapid purification and characterization of DNA topoisomerase I from mouse mammary carcinoma FM3A cells. J. Biol. Chem., 258, 12728-12732 (1983).
38. Kunze, N., Yang, G., Dolberg, M., Sundarp. R., Knippers, R. and Richter, A. Structure of the human type I DNA topoisomerase gene. J. Biol. Chem., 266, 9610-9616 (1991).
39. Matsumoto, Y., Takano, H. and Fojo, T. Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype. Cancer Res., 57, 5086-5092 (1997).
40. Madden, K. R. and Champoux, J. J. Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to camptothecin. Cancer Res., 52, 525-512 (1992).
41. Hann, C., Evans, D. L., Fertala, J., Benedetti, P., Bjornsti, M.-A. and Hall, D. J. Increased camptothecin toxicity in mammalian cells expressing Saccharomyces cerevisiae DNA topoisomcrase I. J. Biol. Chem., 273, 8425-8433 (1998).
42. Andoh, T., Ishii, K., Suzuki, Y., Ikegami, Y., Kusunoki, Y., Takemoto, Y. and Okada, K. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc. Natl. Acad. Sci. USA, 84, 5565-5569 (1987).
43. Tamura, H., Kohchi, C., Yamada, R., Ikeda, T., Koiwai, O., Patterson, E., Keene, J. D., Okada, K., Kjeldsen, E., Nishikawa, K. and Andoh, T. Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase 1 and identification of mutation sites. Nucleic Acids Res., 19, 69-75 (1991).
44. Andoh, T., Tamura, H., Kohchi, C., Yamada, R., Ikeda, T., Koiwai, O., Yasui, Y., Nishizawa, M. and Okada, K. Mechanism of camptothecin resistance in mammalian cells: mutation in topoisomeruse I gene and its implication in enzymatic function. In "Molecular Biology of DNA Topoisomerases and Its Application to Chemotherapy," ed. T. Andoh, H. Ikeda and M. Oguro, pp. 229-235 (1993). CRC Press, Boca Raton.
45. Yanase, K., Sugimoto. Y., Andoh, T. and Tsuruo, T. Retroviral expression of a mutant (Gly-533) human DNA topoisomerase I cDNA confers a dominant form of camptothecin. Int. J. Cancer, 81, 134-140 (1999).
46. Alsner, J., Svejstrup, J. Q., Kjeldsen, E., Sorensen, B. S. and Westgaard, O. Identification of an N-terminal domain of eukaryotic DNA topoisomerase I dispensable for catalytic activity hut essential for in vivo function. J. Biol. Chem., 267, 12408-12411 (1992).
47. Shuman, S., Goldner, M. and Moss, B. Characterization of vaccinia virus DNA topoisomerase I in Escherichia coli. J. Biol. Chem., 263, 16401-16407 (1988).